#USA #Montreal #Sobi #Sanofi #WFH

Sanofi and Sobi Renew Commitment to WFH Humanitarian Aid Program

In a significant announcement, Sanofi and Sobi have extended their partnership with the World Federation of Hemophilia (WFH) to support the humanitarian aid program aimed at addressing the needs of individuals with hemophilia. This renewed contract, which will last for up to five years, underscores the ongoing commitment of these organizations to improve the lives of people suffering from inherited bleeding disorders across the globe.

The collaboration marks the second renewal in over a decade of partnership, demonstrating a shared vision of providing essential care and resources to those in need. Under this new agreement, Sanofi and Sobi will donate up to 100 million international units (IU) of factor therapy annually, specifically targeting those in developing countries.

A Decade of Impact

The recent extension celebrates more than ten years of impactful collaboration since Sanofi and Sobi first responded to WFH's call for action. From 2014 to 2024, they have collectively provided one billion IU of treatment products, positively affecting the lives of over 22,000 patients with inherited bleeding disorders. This substantial contribution has significantly enhanced treatment availability and transformed patient outcomes.

Alaa Hamed, the Global Head of Medical Affairs in Rare Diseases at Sanofi, expressed pride in the new agreement, highlighting its role in creating a sustainable and predictable aid program. “This agreement reaffirms our dedication to addressing unmet needs across the hemophilia landscape worldwide,” said Hamed. “We are committed to continuously enhancing the quality of life for many individuals in developing nations.”

Commitment to the Humanitarian Cause

Lydia Abad-Franch, Chief Medical Officer at Sobi, echoed these sentiments, emphasizing their pride in contributing to the humanitarian program. “Since our initial pledge, we have treated thousands of individuals suffering from hemophilia thanks to our partnership with WFH,” she stated. Both representatives share a strong belief that this renewed agreement is crucial for the future of hemophilia care, promising ongoing advancements in treatment availability.

Cesar Garrido, President of WFH, highlighted the importance of Sanofi and Sobi’s contributions, stating, “Their ongoing support cannot be overstated. This new five-year contract continues a legacy of compassion for the global community suffering from inherited bleeding disorders.”

Mark Skinner, Board Member of WFH USA, added, “The WFH Humanitarian Aid Program exemplifies the impact of collaboration. The support from Sanofi and Sobi has inspired hope, and their contributions have empowered healthcare professionals to better serve those affected.”

The Vision of Treatment for All

The vision of the WFH is simple yet profound: Treatment for All. They aspire to create a world where every person with an inherited bleeding disorder has access to necessary care, irrespective of their condition, gender, or geographical location. The humanitarian aid program serves as a cornerstone in fulfilling this mission, combating barriers to treatment access in under-resourced areas.

The World Federation of Hemophilia, a non-profit organization, actively collaborates with national member organizations and healthcare professionals to improve care for those with inherited bleeding disorders globally. Through training and advocacy, they enable communities to provide better support and resources to those in need.

Sanofi is a global healthcare leader, deeply committed to advancing medicine and improving lives worldwide. It’s philanthropic initiative, Foundation S, plays a crucial role in expanding access to medicines for vulnerable populations.

On the other hand, Sobi is recognized for transforming the lives of individuals suffering from rare diseases through innovative therapies. With a dedicated workforce and a significant revenue base, Sobi is focused on ensuring reliable access to medications across critical healthcare areas.

As both Sanofi and Sobi continue their mission alongside WFH, the renewed partnership serves as a beacon of hope for patients dealing with the challenges of hemophilia. With their collective efforts, thousands are expected to benefit, paving the way for a brighter future in hemophilia care.